Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

Similar articles for PubMed (Select 15647414)

1.

Pharmacokinetic interaction study of indinavir/ritonavir and the enteric-coated capsule formulation of didanosine in healthy volunteers.

la Porte C, Verweij-van Wissen C, van Ewijk N, Aarnoutse R, Koopmans P, Reiss P, Stek M Jr, Hekster Y, Burger D.

J Clin Pharmacol. 2005 Feb;45(2):211-8.

PMID:
15647414
4.

Lopinavir/ritonavir: a review of its use in the management of HIV infection.

Cvetkovic RS, Goa KL.

Drugs. 2003;63(8):769-802. Review.

PMID:
12662125
6.

A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.

Marcelín-Jiménez G, Angeles-Moreno AP, Contreras-Zavala L, Morales-Martínez M, Rivera-Espinosa L.

Clin Ther. 2009 Sep;31(9):2002-11. doi: 10.1016/j.clinthera.2009.09.016.

PMID:
19843490
7.

The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteers.

Aarnoutse RE, Grintjes KJ, Telgt DS, Stek M Jr, Hugen PW, Reiss P, Koopmans PP, Hekster YA, Burger DM.

Clin Pharmacol Ther. 2002 Jan;71(1):57-67.

PMID:
11823758
8.

Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavir.

Aarnoutse RE, Wasmuth JC, Fätkenheuer G, Schneider K, Schmitz K, de Boo TM, Reiss P, Hekster YA, Burger DM, Rockstroh JK.

Antivir Ther. 2003 Aug;8(4):309-14.

PMID:
14518700
9.

Effects of didanosine formulations on the pharmacokinetics of amprenavir.

Shelton MJ, Giovanniello AA, Cloen D, Berenson CS, Keil K, DiFrancesco R, Hewitt RG.

Pharmacotherapy. 2003 Jul;23(7):835-42.

PMID:
12885096
10.

Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers.

Hsu A, Granneman GR, Cao G, Carothers L, Japour A, El-Shourbagy T, Dennis S, Berg J, Erdman K, Leonard JM, Sun E.

Antimicrob Agents Chemother. 1998 Nov;42(11):2784-91.

12.

A once-daily HAART regimen containing indinavir + ritonavir plus one or two nucleoside reverse transcriptase inhibitors (PIPO study).

Burger DM, Aarnoutse RE, Dieleman JP, Gyssens IC, Nouwen J, de Marie S, Koopmans PP, Stek M Jr, van der Ende ME.

Antivir Ther. 2003 Oct;8(5):455-61.

PMID:
14640393
13.

Effect of food on the oral bioavailability of didanosine from encapsulated enteric-coated beads.

Damle BD, Yan JH, Behr D, O'Mara E, Nichola P, Kaul S, Knupp C.

J Clin Pharmacol. 2002 Apr;42(4):419-27.

PMID:
11936567
14.

Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals.

Veldkamp AI, van Heeswijk RP, Mulder JW, Meenhorst PL, Schreij G, van der Geest S, Lange JM, Beijnen JH, Hoetelmans RM.

J Acquir Immune Defic Syndr. 2001 Aug 1;27(4):344-9.

PMID:
11468422
16.

A pilot trial of indinavir, ritonavir, didanosine, and lamivudine in a once-daily four-drug regimen for HIV infection.

Mole L, Schmidgall D, Holodniy M.

J Acquir Immune Defic Syndr. 2001 Jul 1;27(3):260-5.

PMID:
11464145
18.

Dose-finding study of a once-daily indinavir/ritonavir regimen.

Hugen PW, Burger DM, ter Hofstede HJ, Koopmans PP, Stek M, Hekster YA, Reiss P, Lange JM.

J Acquir Immune Defic Syndr. 2000 Nov 1;25(3):236-45.

PMID:
11115954
19.

Pharmacokinetic comparison of sustained- and immediate-release oral formulations of cilostazol in healthy Korean subjects: a randomized, open-label, 3-part, sequential, 2-period, crossover, single-dose, food-effect, and multiple-dose study.

Lee D, Lim LA, Jang SB, Lee YJ, Chung JY, Choi JR, Kim K, Park JW, Yoon H, Lee J, Park MS, Park K.

Clin Ther. 2011 Dec;33(12):2038-53. doi: 10.1016/j.clinthera.2011.10.024. Epub 2011 Nov 29.

PMID:
22129569
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk